LivaNova PLC

While the long-term uptrend remains intact since mid-2025, a recent Support Failure and breach of the 9/21 EMA zone have triggered a corrective pullback within Stage 2. Price holds above the rising 50 DMA and 200 DMA, preserving the uptrend, but short-term momentum is unfavorable for new buys. Medium-term bias remains bullish, suggesting selective deferred entries on stabilization or reclaim of the EMA zone.

• ↑Q1 revenue $362 M (+11% YoY) and adjusted EPS $0.98 beat $0.85 consensus.
• ↑Full-year revenue guidance raised to 7–8%, up from prior 6–7%.
• ↓Adjusted free cash flow declined to $4 M from $20 M, stressing liquidity.